- Q1 2024 Lucid Diagnostics Inc Earnings Call TranscriptMay 13, 2024$0.95 (+0.59%)Earnings
- Q4 2023 Lucid Diagnostics Inc Earnings Call TranscriptMar 26, 2024$0.99 (-6.60%)Earnings
- Q3 2023 Lucid Diagnostics Inc Earnings Call TranscriptNov 14, 2023$1.3 (+12.07%)Earnings
- Q2 2023 Lucid Diagnostics Inc Earnings Call TranscriptAug 15, 2023$1.49 (+0.34%)Earnings
- Lucid Diagnostics Inc Annual Shareholders Meeting TranscriptJun 21, 2023
- Q4 2022 Lucid Diagnostics Inc Earnings Call TranscriptMar 14, 2023$1.72 (+6.83%)Earnings
- PAVmed Inc, Lucid Diagnostics Inc and Veris Health Inc Strategic Business Update Call TranscriptJan 17, 2023
- Q3 2022 Lucid Diagnostics Inc Earnings Call TranscriptNov 14, 2022$2.27 (+1.79%)Earnings
- Q2 2022 Lucid Diagnostics Inc Earnings Call TranscriptAug 15, 2022$3.35 (-1.18%)Earnings
- Lucid Diagnostics Inc Annual Shareholders Meeting TranscriptJun 21, 2022
- Q1 2022 Lucid Diagnostics Inc Earnings Call TranscriptMay 11, 2022$1.86 (-7.46%)Earnings
- Lucid Diagnostics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 12, 2022
Lucid Diagnostics Inc at Needham Healthcare Conference (Virtual) Transcript
Thanks for joining us again at the 21st Annual Needham Healthcare Conference. I'm Mike Matson, and I lead the medtech equity research team here at Needham & Company. I am pleased to introduce Lucid Diagnostics. We have Lucid's CEO, Lishan Aklog; CFO, Dennis McGrath; and VP of Investor Relations, Adrian Miller.
Instead of a standard presentation, we are going to do a Q&A session. If you have any questions you would like me to ask, you can submit them electronically through the Needham conference website or feel free to email them to me at [email protected]. And I'll do my best to fit them in.
So as I noted, we are going to go straight into Q&A here.
Questions & Answers
So we'll start with EsoGuard. You've developed this innovative test and sample collection system for esophageal precancer, called EsoGuard and EsoCheck. It was wondering if you could give us an overview of esophageal cancer, why it's so deadly, and what
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)